← All patents

US20230069749A1

Use of poziotinib for the treatment of cancers with nrg1 fusions

University of Texas System

Abstract

Provided herein are methods of selecting cancer patients for treatment with poziotinib as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with poziotinib alone or in …

University
University of Texas System
Assignee
Board Of Regents, The University Of Texas System
Inventor
John Heymach
Priority date
January 29, 2020
Filing date
January 29, 2021
Publication date
March 02, 2023
Language
en
Metadata fetched
August 29, 2026 00:31